Atom Investors’s Akero Therapeutics AKRO Stock Holding History

Atom Investors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,838	Closed	-$2.18M	–	568
2025 Q3	$2.18M	Buy	45,838 +31,657	+223%	+$1.53M	0.17%	158
2025 Q2	$757K	Sell	14,181 -29,970	-68%	-$1.36M	0.07%	291
2025 Q1	$1.79M	Sell	44,151 -3,549	-7%	-$150K	0.22%	135
2024 Q4	$1.33M	Buy	+47,700	New	+$1.44M	0.16%	186
2024 Q3	–	Sell	-21,050	Closed	-$494K	–	466
2024 Q2	$494K	Buy	21,050 +6,278	+42%	+$134K	0.05%	334
2024 Q1	$373K	Sell	14,772 -30,922	-68%	-$743K	0.05%	377
2023 Q4	$1.07M	Buy	45,694 +26,614	+139%	+$525K	0.19%	177
2023 Q3	$965K	Buy	+19,080	New	+$888K	0.22%	142

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Atom Investors's AKRO Position: Q4 2025 in Review

Atom Investors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 45,838 shares — an estimated $2.18M sold.

Atom Investors first reported a position in AKRO in Q3 2023 and held it in 8 quarters. The position peaked at $2.18M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Atom Investors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 45,838 Akero Therapeutics shares in Q4 2025, an estimated $2.18M.
Atom Investors first reported a position in Akero Therapeutics in Q3 2023 and held it in 8 quarters.
Atom Investors's Akero Therapeutics position peaked at $2.18M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.